4min chapter

Cardionerds: A Cardiology Podcast cover image

306. Decompensated Right Ventricular Failure in Pulmonary Arterial Hypertension with Dr. Mardi Gomberg-Maitland and Dr. Rachel Damico

Cardionerds: A Cardiology Podcast

CHAPTER

The Different Pathways for Treatment of Pulmonary Artery Hypertension

There are three pathways that we can approach with FDA approved drugs for pulmonary arterial hypertension. PD5 inhibitors represent one of the calming classes and again, probably the most common use drugs were the PDE5 inhibitors. The second pathway we target is the endothelion pathway. There's too much endothelion one when patients have pulmonary chiral hypertension. Inelational drugs like Taebeso have to be delivered to a specialized device.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode